Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

44.52 +0.96 (+2.20%)
Official Closing Price Updated: 4:10 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,481,985
Open 44.19
Bid (Size) 44.27 (4)
Ask (Size) 44.50 (1)
Prev. Close 43.56
Today's Range 43.81 - 44.54
52wk Range 37.80 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
GSK Turnaround Story
GSK is already gearing up for what it hopes will be a bright future. On April 13, GlaxoSmithKline announced a $1.9 billion deal to purchase a U.S. biotech company, Sierra Oncology. 
Via Talk Markets
GlaxoSmithKline: Dividend Insights
Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK). 
Via Benzinga

Performance

YTD
+1.95%
+1.95%
1 Month
-2.88%
-2.88%
3 Month
+3.44%
+3.44%
6 Month
+7.04%
+7.04%
1 Year
+14.07%
+14.07%

More News

Read More
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Via Talk Markets
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
Via Benzinga
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
Via Investor's Business Daily
Recap: GlaxoSmithKline Q1 Earnings
Via Benzinga
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029
Via Benzinga
Dividend Income Update April 2022
Via Talk Markets
GlaxoSmithKline Clocks 32% Topline Growth Buoyed By COVID-19 Therapy, Shingrix Vaccine
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Via Benzinga
GlaxoSmithKline's Earnings Outlook
Via Benzinga
Public-health Authorities in US, UK, Probe Mysterious Cases Of Severe Hepatitis In Young Kids: WSJ
Via Benzinga
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Via Benzinga
Quest Diagnostics' COVID-19 Testing Sales Decline 28% In Q1; Lifts FY22 EPS Guidance
Via Benzinga
4 Undervalued Biotech Stocks to Add to Your Buy List
Via InvestorPlace
As Evolving Pandemic Response, Officials Shift To Personal Choice On COVID-19 Boosters, Masks: WSJ
Via Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Via Benzinga
Why Is Sierra Oncology (SRRA) Stock Up Today?
Via InvestorPlace
Sierra Oncology Stock Is Soaring: Here's Why
Via Benzinga
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares
Via Investor's Business Daily
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Via Benzinga
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Watch For Continued Gains In Shares Of GlaxoSmithKline PLC (GSK)
Via Benzinga
Highly Rated GlaxoSmithKline Eyes Breakout After Racking Up Series Of Wins
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.